North America Multi Cancer Early Detection Market Size, Trends and Insights By Type (Blood-Based Tests, Imaging-Based Tests, Genomic Profiling, Tissue-Based Tests), By End Use (Hospitals, Diagnostic Laboratories, Cancer Research Institutions, Others), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2023–2032


Report Code: CMI24228

Published Date: June 2023

Pages: 220+

Category: North America

Report Snapshot

CAGR: 17.2%
273.1M
2022
321.7M
2023
1345.2M
2032

Source: CMI

Study Period: 2023-2032
Fastest Growing Market: North America
Largest Market: North America

Major Players

  • Illumina Inc.
  • Exact Sciences Corporation
  • GRAIL Inc.
  • Guardant Health Inc.
  • Foundation Medicine Inc. (Roche)
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

As per the current market research conducted by CMI Team, the North America Multi Cancer Early Detection Market is expected to record a CAGR of 17.1% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 273.1 Million. By 2032, the valuation is anticipated to reach USD 1345.2 Million.

The North America Multi Cancer Early Detection Market refers to the market segment focused on the production, development and distribution of tools, technologies, and services for detecting different types of cancer at an early stage.

This market includes various approaches, such as blood-based tests, liquid biopsies, genomic profiling, and other advanced techniques that help in the early detection of different forms of cancer. The main goal is to enable timely intervention and treatment of cancer, hence improving patient outcomes and reducing cancer-related morbidity and mortality rates in the North American region.

North America Multi Cancer Early Detection Market – Significant Growth Factors

The North America Multi Cancer Early Detection Market presents significant growth opportunities due to several factors:

  • Increasing Prevalence of Cancer: The rising prevalence of cancer disease in the North America region is one of major drivers for the market’s growth. There is a growing need for effective early detection strategies to improve patient outcomes due to the continuous rise in cancer rates in the region.
  • Emphasis on Early Detection: There is an increase in awareness among healthcare providers and patients regarding the advantages of early cancer detection for its treatment. The early identification of disease helps in timely treatment interventions, resulting to a better prognosis and increased chances of successful treatment. This emphasis on early detection fuels the demand for multi-cancer screening and diagnostic tools.
  • Technological Advancements in Diagnostic Technologies: There have been significant advancements in diagnostic technologies for more accurate and efficient methods of detecting multiple types of cancer. Techniques such as liquid biopsies, genomic profiling, and others have shown promising results in identifying cancer at its early stages, hence driving the market growth.
  • Government Initiatives and Funding: Governments and healthcare organizations in North America are increasingly investing in cancer research, innovation, screening programs, and early detection initiatives. The motive of these initiatives is to improve cancer outcomes and reduce the cost of advanced-stage cancer treatment for the general public. Government support and funding has resulted in favourable environment for market growth.
  • Technological Innovations: There has been a continuous development of new technologies for diagnosing cancer, such as next-generation sequencing, artificial intelligence, and machine learning that are contributing to the growth of the multi-cancer early detection market. These innovations have enhanced the accuracy, efficiency, and accessibility of diagnostic tests, hence driving market expansion in North America.

North America Multi Cancer Early Detection Market  – Mergers and Acquisitions

The North America Multi Cancer Early Detection Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the North America Multi Cancer Early Detection Market  include:

  • Illumina’s Acquisition of GRAIL: Illumina, a leading genomic sequencing company, announced its acquisition of GRAIL, a biotechnology company focused on multi-cancer early detection in September 2020. The acquisition aimed to capitalize on GRAIL’s expertise in liquid biopsy technology and expedite the development of innovative solutions for cancer screening.
  • Exact Sciences’ Acquisition of Thrive Earlier Detection: In January 2020, Exact Sciences, a molecular diagnostics company, purchased Thrive Earlier Detection, a healthcare company dedicated to the development of early-stage cancer screening tests. The acquisition aimed to merge Thrive’s proficiency in blood-based, multi-cancer screening with Exact Sciences’ capabilities in molecular diagnostics.
  • Roche’s Acquisition of Foundation Medicine: In 2018, Roche, a global pharmaceutical and diagnostics company, acquired Foundation Medicine, a specialized molecular information company focused on comprehensive genomic profiling. The acquisition sought to enhance Roche’s position in the personalized healthcare sector and advance its initiatives in early cancer detection and treatment.

These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the North America Multi Cancer Early Detection Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

North America Multi Cancer Early Detection Market Multi Cancer Early Detection Market Europe Multi Cancer Early Detection Market
CAGR 17.1% (Approx) CAGR 16.5% (Approx) CAGR 14.8% (Approx)
US$ 1345.2 Million by 2032 USD 3186.8 Million by 2030 USD 1150.3 Million by 2032

North America Multi Cancer Early Detection Market – Significant Threats

The North America Multi Cancer Early Detection Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

  • Regulatory Challenges: The multi cancer early detection market in North America faces various regulatory challenges. The approval of new screening tests and developments involves stringent regulatory oversight to ensure safety, efficacy, and accurate results. Regulatory hurdles and delays can hinder the growth of the market and effect the adoption of innovative solutions.
  • Reimbursement Issues: Unfavourable reimbursement policies and coverage for multi cancer early detection tests can pose a significant threat to the industry. The lack of enough reimbursement or less coverage by insurance providers can hinder patient access to such tests, thereby affecting market demand and growth. Hence, the ambiguity in reimbursement policies can discourage healthcare providers from offering these tests, impacting market expansion.
  • Expensive: The high cost of multi cancer early detection tests can pose some challenges to the growth of the market. Advanced technologies and genomic profiling techniques used in these tests can be very costly, making them less accessible to the general population, especially for people with low income. The high costs of testing can limit adoption rates and lead to slow down market penetration.
  • Lack of Awareness and Education: There is very limited awareness and knowledge about the advantages of multi cancer early detection that hinders market growth. Many people are not aware of the availability of such tests or the potential benefits they offer in terms of successful treatment outcomes. Educational initiatives targeting healthcare professionals, patients, and the general public are crucial for increasing awareness and driving market expansion.

Report Scope

Feature of the Report Details
Market Size in 2023 USD 321.7 Million
Projected Market Size in 2032 USD 1345.2 Million
Market Size in 2022 USD 273.1 Million
CAGR Growth Rate 17.2% CAGR
Base Year 2022
Forecast Period 2023-2032
Key Segment By Type, End Use and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Category-Wise Insights

By Type:

  • Blood-Based Tests: These tests include a collection of blood samples to detect specific biomarkers or genetic alterations that can be associated with different types of cancer. Some of its examples include circulating tumour DNA (ctDNA) analysis, protein-based assays, and other liquid biopsy techniques.
  • Imaging-Based Tests: Imaging technologies include mammography, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans that can be leveraged to detect suspicious lesions or tumors that may reflect the presence of cancer.
  • Genomic Profiling: Genomic profiling technique includes analyzing the genetic makeup of tumor cells to detect specific mutations, gene expression patterns, or alterations associated with various cancer stages. This type of testing provides valuable insights for personalized treatment options and potential targeted therapies.
  • Tissue-Based Tests: These tests involve the analysis of tissue samples that are collected through biopsies or surgical procedures. These techniques help to get to know the presence of cancer cells, their characteristics, and their stage of development.

By End User Channel:

  • Hospitals and Clinics: Hospitals and clinics are one of the major end users in cancer detection and diagnosis market. They provide the required infrastructure and medical staff required to perform various diagnostic tests and procedures, such as blood-based tests, imaging scans, and tissue biopsies.
  • Diagnostic Laboratories: Various diagnostic laboratories have the expertise to analyze samples and conduct tests using specific diagnostic techniques like genomic profiling or liquid biopsy analysis. These labs offer valuable diagnostic insights to doctors or hospitals that helps in the early detection of various types of cancer and for successful treatment.
  • Cancer Research Institutions: Research institutions also play an important role in pioneering innovative technologies and methodologies for multi-cancer early detection. They conduct clinical trials, validate diagnostic tools, and contribute to the advancement of scientific knowledge in the field of cancer detection and diagnosis. Their work helps drive progress in improving early detection strategies and enhancing patient outcomes.

North America Multi Cancer Early Detection Market 2023–2032 (By Million)

www.custommarketinsight.com

North America Multi Cancer Early Detection Market  – Regional Analysis

The North America Multi Cancer Early Detection Market is segmented into various regions, including the United States, Canada and Mexico.

Here is a brief overview of each region:

  • United States: The North America Multi Cancer Early Detection Market sees significant growth in the United States. With its well-established healthcare infrastructure, advanced research capabilities, and high cancer prevalence, the country serves as a key market. The presence of major market players, renowned research institutions, and government initiatives focused on cancer detection contribute to the market’s expansion in the United States.
  • Canada: Canada also holds a considerable share of the North America Multi Cancer Early Detection Market. The country boasts a robust healthcare system, renowned research institutions, and a growing emphasis on early cancer detection. Government initiatives, collaborative efforts among research organizations, and increasing awareness among healthcare providers and patients play crucial roles in driving market growth in Canada.
  • Mexico: Mexico is an emerging market for multi-cancer early detection in North America. The country’s healthcare sector is evolving, witnessing increased investments in cancer research, infrastructure development, and awareness campaigns. The growing prevalence of cancer and efforts to enhance early detection capabilities contribute to the market’s growth in Mexico.

North America Multi Cancer Early Detection Market 2023–2032 (By End Use)

www.custommarketinsight.com

Competitive Landscape – North America Multi Cancer Early Detection Market

The North America Multi Cancer Early Detection Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

  • Illumina Inc.
  • Exact Sciences Corporation
  • GRAIL Inc.
  • Guardant Health Inc.
  • Foundation Medicine Inc. (Roche)
  • Biocept Inc.
  • Thrive Earlier Detection Corp. (Exact Sciences Corporation)
  • Natera Inc.
  • Freenome Holdings Inc.
  • Genomic Health Inc. (Exact Sciences Corporation)
  • Bio-Rad Laboratories Inc.
  • Personal Genome Diagnostics Inc.
  • Biodesix Inc.
  • Sysmex Corporation
  • ArcherDX Inc. (Invitae Corporation)
  • Others

The North America Multi Cancer Early Detection Market is segmented as follows:

By Type

  • Blood-Based Tests
  • Imaging-Based Tests
  • Genomic Profiling
  • Tissue-Based Tests

By End Use

  • Hospitals
  • Diagnostic Laboratories
  • Cancer Research Institutions
  • Others

On the basis of North America Geography

  • U.S
  • Canada
  • Mexico

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market research methodology
  • Chapter 2. Executive Summary
    • 2.1 North America Multi Cancer Early Detection Market, (2023 – 2032) (USD Million)
    • 2.2 North America Multi Cancer Early Detection Market : snapshot
  • Chapter 3. North America Multi Cancer Early Detection Market – Industry Analysis
    • 3.1 North America Multi Cancer Early Detection Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Increasing Prevalence of Cancer
      • 3.2.2 Emphasis on Early Detection
      • 3.2.3 Technological Advancements in Diagnostic Technologies
      • 3.2.4 Government Initiatives and Funding
      • 3.2.5 Technological Innovations.
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market attractiveness analysis By Type
      • 3.7.2 Market attractiveness analysis By End Use
  • Chapter 4. North America Multi Cancer Early Detection Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 North America Multi Cancer Early Detection Market: company market share, 2022
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. North America Multi Cancer Early Detection Market – Type Analysis
    • 5.1 North America Multi Cancer Early Detection Market overview: By Type
      • 5.1.1 North America Multi Cancer Early Detection Market share, By Type, 2022 and 2032
    • 5.2 Blood-Based Tests
      • 5.2.1 North America Multi Cancer Early Detection Market by Blood-Based Tests , 2023 – 2032 (USD Million)
    • 5.3 Imaging-Based Tests
      • 5.3.1 North America Multi Cancer Early Detection Market by Imaging-Based Tests, 2023 – 2032 (USD Million)
    • 5.4 Genomic Profiling
      • 5.4.1 North America Multi Cancer Early Detection Market by Genomic Profiling, 2023 – 2032 (USD Million)
    • 5.5 Tissue-Based Tests
      • 5.5.1 North America Multi Cancer Early Detection Market by Tissue-Based Tests, 2023 – 2032 (USD Million)
  • Chapter 6. North America Multi Cancer Early Detection Market – End Use Analysis
    • 6.1 North America Multi Cancer Early Detection Market overview: By End Use
      • 6.1.1 North America Multi Cancer Early Detection Market share, By End Use, 2022 and 2032
    • 6.2 Hospitals
      • 6.2.1 North America Multi Cancer Early Detection Market by Hospitals, 2023 – 2032 (USD Million)
    • 6.3 Diagnostic Laboratories
      • 6.3.1 North America Multi Cancer Early Detection Market by Diagnostic Laboratories, 2023 – 2032 (USD Million)
    • 6.4 Cancer Research Institutions
      • 6.4.1 North America Multi Cancer Early Detection Market by Cancer Research Institutions , 2023 – 2032 (USD Million)
    • 6.5 Others
      • 6.5.1 North America Multi Cancer Early Detection Market by Others, 2023 – 2032 (USD Million)
  • Chapter 7. North America Multi Cancer Early Detection Market – Regional Analysis
    • 7.1 North America Multi Cancer Early Detection Market Regional Overview
    • 7.2 North America Multi Cancer Early Detection Market Share, by Region, 2022 & 2032 (USD Million)
  • Chapter 8. Company Profiles
    • 8.1 Illumina Inc.
      • 8.1.1 Overview
      • 8.1.2 Financials
      • 8.1.3 Product Portfolio
      • 8.1.4 Business Strategy
      • 8.1.5 Recent Developments
    • 8.2 Exact Sciences Corporation
      • 8.2.1 Overview
      • 8.2.2 Financials
      • 8.2.3 Product Portfolio
      • 8.2.4 Business Strategy
      • 8.2.5 Recent Developments
    • 8.3 GRAIL Inc.
      • 8.3.1 Overview
      • 8.3.2 Financials
      • 8.3.3 Product Portfolio
      • 8.3.4 Business Strategy
      • 8.3.5 Recent Developments
    • 8.4 Guardant Health Inc.
      • 8.4.1 Overview
      • 8.4.2 Financials
      • 8.4.3 Product Portfolio
      • 8.4.4 Business Strategy
      • 8.4.5 Recent Developments
    • 8.5 Foundation Medicine Inc. (Roche)
      • 8.5.1 Overview
      • 8.5.2 Financials
      • 8.5.3 Product Portfolio
      • 8.5.4 Business Strategy
      • 8.5.5 Recent Developments
    • 8.6 Biocept Inc.
      • 8.6.1 Overview
      • 8.6.2 Financials
      • 8.6.3 Product Portfolio
      • 8.6.4 Business Strategy
      • 8.6.5 Recent Developments
    • 8.7 Thrive Earlier Detection Corp. (Exact Sciences Corporation)
      • 8.7.1 Overview
      • 8.7.2 Financials
      • 8.7.3 Product Portfolio
      • 8.7.4 Business Strategy
      • 8.7.5 Recent Developments
    • 8.8 Natera Inc.
      • 8.8.1 Overview
      • 8.8.2 Financials
      • 8.8.3 Product Portfolio
      • 8.8.4 Business Strategy
      • 8.8.5 Recent Developments
    • 8.9 Freenome Holdings Inc.
      • 8.9.1 Overview
      • 8.9.2 Financials
      • 8.9.3 Product Portfolio
      • 8.9.4 Business Strategy
      • 8.9.5 Recent Developments
    • 8.10 Genomic Health Inc. (Exact Sciences Corporation)
      • 8.10.1 Overview
      • 8.10.2 Financials
      • 8.10.3 Product Portfolio
      • 8.10.4 Business Strategy
      • 8.10.5 Recent Developments
    • 8.11 Bio-Rad Laboratories Inc.
      • 8.11.1 Overview
      • 8.11.2 Financials
      • 8.11.3 Product Portfolio
      • 8.11.4 Business Strategy
      • 8.11.5 Recent Developments
    • 8.12 Personal Genome Diagnostics Inc.
      • 8.12.1 Overview
      • 8.12.2 Financials
      • 8.12.3 Product Portfolio
      • 8.12.4 Business Strategy
      • 8.12.5 Recent Developments
    • 8.13 Biodesix Inc.
      • 8.13.1 Overview
      • 8.13.2 Financials
      • 8.13.3 Product Portfolio
      • 8.13.4 Business Strategy
      • 8.13.5 Recent Developments
    • 8.14 Sysmex Corporation
      • 8.14.1 Overview
      • 8.14.2 Financials
      • 8.14.3 Product Portfolio
      • 8.14.4 Business Strategy
      • 8.14.5 Recent Developments
    • 8.15 ArcherDX Inc. (Invitae Corporation)
      • 8.15.1 Overview
      • 8.15.2 Financials
      • 8.15.3 Product Portfolio
      • 8.15.4 Business Strategy
      • 8.15.5 Recent Developments
    • 8.16 Others.
      • 8.16.1 Overview
      • 8.16.2 Financials
      • 8.16.3 Product Portfolio
      • 8.16.4 Business Strategy
      • 8.16.5 Recent Developments
List Of Figures

Figures No 1 to 17

List Of Tables

Tables No 1 to 2

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2030

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2030
  • Market revenue estimates and forecasts up to 2030, by technology
  • Market revenue estimates and forecasts up to 2030, by application
  • Market revenue estimates and forecasts up to 2030, by type
  • Market revenue estimates and forecasts up to 2030, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Illumina Inc.
  • Exact Sciences Corporation
  • GRAIL Inc.
  • Guardant Health Inc.
  • Foundation Medicine Inc. (Roche)
  • Biocept Inc.
  • Thrive Earlier Detection Corp. (Exact Sciences Corporation)
  • Natera Inc.
  • Freenome Holdings Inc.
  • Genomic Health Inc. (Exact Sciences Corporation)
  • Bio-Rad Laboratories Inc.
  • Personal Genome Diagnostics Inc.
  • Biodesix Inc.
  • Sysmex Corporation
  • ArcherDX Inc. (Invitae Corporation)
  • Others

FAQs

The key factors driving the Market are Increasing Prevalence of Cancer, Emphasis on Early Detection, Technological Advancements in Diagnostic Technologies, Government Initiatives and Funding And Technological Innovations.

The key players operating in the North America Multi Cancer Early Detection Market are Illumina Inc., Exact Sciences Corporation, GRAIL Inc., Guardant Health Inc., Foundation Medicine Inc. (Roche), Biocept Inc., Thrive Earlier Detection Corp. (Exact Sciences Corporation), Natera Inc., Freenome Holdings Inc., Genomic Health Inc. (Exact Sciences Corporation), Bio-Rad Laboratories Inc., Personal Genome Diagnostics Inc., Biodesix Inc., Sysmex Corporation, ArcherDX Inc. (Invitae Corporation), Others.

The North America Multi Cancer Early Detection Market is expanding growth with a CAGR of approximately 17.2% during the forecast period (2023 to 2032).

The North America Multi Cancer Early Detection Market size was valued at USD 273.1 Million in 2022 and it is projected to reach around USD 1345.2 Million by 2032.

PURCHASE OPTIONS

$

2850


$

3850


$

4850


$

1750


powerbi pdf
$

5400

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • PDF, Excel, Power Point and Power BI.
  • Every Year Free Update ( Apr – Apr)
  • Personalized market brief by author
  • Can be accessible by unlimited users.
  • Free 50% or 90 hours of customization.
  • Up to 50 Company Profiles
  • Free post-sale service assistance with guarantee
  • 40% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account team.
  • Service guarantee available.

Want to customize this report?
100% FREE CUSTOMIZATION!